
EPO vs UPC: Why diverging standards on patentability of Amgen’s PCSK9 Therapy could signal strategic crossroads for Biotech Innovators
A tale of two tribunals is unfolding over Amgen’s European patent for antibody PCSK9 inhibitors. Two IP patent attorney Sheena Linehan unpicks the potentially profound